Mikirova N.A.,Bio Communications Research Institute |
Mikirova N.A.,Aidan Products, LLC |
Jackson J.A.,The Center For The Improvement Of Human Functioning International |
Jackson J.A.,Aidan Products, LLC |
And 23 more authors.
Journal of Translational Medicine | Year: 2010
The medical significance of circulating endothelial or hematopoietic progenitors is becoming increasing recognized. While therapeutic augmentation of circulating progenitor cells using G-CSF has resulted in promising preclinical and early clinical data for several degenerative conditions, this approach is limited by cost and inability to perform chronic administration. Stem-Kine is a food supplement that was previously reported to augment circulating EPC in a pilot study. Here we report a trial in 18 healthy volunteers administered Stem-Kine twice daily for a 2 week period. Significant increases in circulating CD133 and CD34 cells were observed at days 1, 2, 7, and 14 subsequent to initiation of administration, which correlated with increased hematopoietic progenitors as detected by the HALO assay. Augmentation of EPC numbers in circulation was detected by KDR-1/CD34 staining and colony forming assays. These data suggest Stem-Kine supplementation may be useful as a stimulator of reparative processes associated with mobilization of hematopoietic and endothelial progenitors. © 2010 Mikirova et al; licensee BioMed Central Ltd.
Aidan Products, LLC | Date: 2010-12-09
Compositions of matter, uses, and formulations of food supplements/nutrients capable of eliciting mobilization of various stem/progenitor cells, including hematopoietic stem cells and endothelial progenitor cells are disclosed. In one embodiment a formulation contains a mixture of ellagic acid, vitamin D3, beta 1,3 glucan and a ferment of the bacterium, Lactobacillus fermentum, with an extract of green tea, extract of goji berries, and extract of the root of astragalus added prior to fermentation. Said formulation, originally developed as an antioxidant/immune stimulator was found to have the unexpected property of eliciting stem/progenitor cell mobilization.
Aidan Products, LLC | Date: 2012-09-13
Described are methods of treating macular edema, as well as other complications of ocular inflammation, through the administration of various stem cell populations and conditioned media thereof. In one embodiment a patient suffering from macular edema is administered an intramuscular dose of media conditioned by placental mesenchymal stem cells at a sufficient concentration and frequency to elicit a reduction in ocular inflammation. Other embodiments of the invention teach intra-ocular, intravenous, sublingual, and oral means of delivery conditioned media from various stem cell populations that has been optimized for anti-inflammatory, regenerative, and immune modulatory properties.